Kainova reports positive results from phase I EPRAD study of DT-9081, an oral EP4 receptor antagonist, in advanced solid tumours: Montreal, Canada Thursday, March 12, 2026, 17:00 ...
The GPCRact AI model goes beyond AlphaFold3 by predicting whether drugs functionally activate G-protein-coupled receptors ...
Chief Executive Officer Sean A MacDonald added: “The successful completion of this Phase I study represents an important step for Kainova Therapeutics, highlighting the strength of our innovative ...
Cone snails deploy sophisticated venom cocktails to paralyse prey. Anthony King talks to the researchers harnessing these ...
Executives from Crinetics Pharmaceuticals (NASDAQ:CRNX) used an investor discussion at TD Cowen’s 46th Annual Healthcare Conference to highlight early U.S. commercial progress for its newly launched ...
Septerna has reported positive past Phase 1 results for SEP-631, an oral negative allosteric modulator of MRGPRX2, showing robust target engagement, functional pathway blockade, and tolerability ...
SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as ...
Adhesion GPCRs are a large class of surface proteins that recognize chemical and mechanical stimuli in the body. The rapidly expanding body of knowledge on the therapeutic targeting of these receptors ...
Researchers at Leipzig University and Shandong University have summarised the therapeutic potential of these receptors in a high-profile study. At present, 17 of the 33 known human adhesion GPCRs are ...
Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results